Ã÷ÐDzúÆ·
Star Products
-

ÉÆÔóƽ
ÆÕ¬¸ñÁÐ͡ƬPrusogliptin Tablets
ÉÆÔóƽ
ÆÕ¬¸ñÁÐ͡ƬPrusogliptin Tablets
˳Ӧ֢£º±¾Æ·ÊÊÓÃÓÚ¸ÄÉÆ2ÐÍÌÇÄò²¡»¼ÕßµÄѪÌÇ¿ØÖÆ¡£¡£¡£¡£¡£¡£
-

¶÷ÒæÌ¹
×¢ÉäÓðÂÂíÖéµ¥¿¹×¢ÉäÒºOmalizumab for Injection
¶÷ÒæÌ¹
×¢ÉäÓðÂÂíÖéµ¥¿¹×¢ÉäÒºOmalizumab for Injection
˳Ӧ֢£º½ÓÄÉH1¿¹×é°·Ò©ÖÎÁƺóÈÔÓÐÖ¢×´µÄ³ÉÈ˺ÍÇàÉÙÄ꣨12Ëê¼°ÒÔÉÏ£©ÂýÐÔ×Ô¾õÐÔÝ¡ÂéÕÕß¡£¡£¡£¡£¡£¡£
-

¶÷ÊæÐÒ
¶÷ÀÊËհݵ¥¿¹×¢ÉäÒºEnlonstobart Injection
¶÷ÊæÐÒ
¶÷ÀÊËհݵ¥¿¹×¢ÉäÒºEnlonstobart Injection
˳Ӧ֢£º¼ÈÍù½ÓÊܺ¬²¬»¯ÁÆÖÎÁÆÊ§°ÜµÄPD-L1±í´ïÑôÐÔ£¨CPS¡Ý1£©µÄ¸´·¢»ò×ªÒÆÐÔ¹¬¾±°©»¼Õß¡£¡£¡£¡£¡£¡£
-

½òÁ¢Ì©
ÄɳË÷°Ýµ¥¿¹×¢ÉäÒºNarlumosbart Injection
½òÁ¢Ì©
ÄɳË÷°Ýµ¥¿¹×¢ÉäÒºNarlumosbart Injection
˳Ӧ֢£ºÓÃÓÚÖÎÁƲ»¿ÉÊÖÊõÇгý»òÊÖÊõÇгý¿ÉÄܵ¼ÖÂÑÏÖØ¹¦Ð§ÕϰµÄ¹Ç¾Þϸ°ûÁö¡£¡£¡£¡£¡£¡£
-

º£ÒæÌ¹
¹ÈÃÀÌæÄáÆ¬Glumetinib
º£ÒæÌ¹
¹ÈÃÀÌæÄáÆ¬Glumetinib
˳Ӧ֢£ºÊÊÓÃÓÚ¾ßÓмäÖÊ-ÉÏÆ¤×ª»¯Òò×Ó£¨MET£©ÍâÏÔ×Ó14Ìø±äµÄ¾Ö²¿ÍíÆÚ»ò×ªÒÆÐÔ·ÇСϸ°û·Î°©£¨NSCLC£©µÄÖÎÁÆ¡£¡£¡£¡£¡£¡£
-

¶÷±ØÆÕÈí½ºÄÒ
¶¡±½ÌªÈí½ºÄÒButylphthalide Soft Capsules
¶÷±ØÆÕÈí½ºÄÒ
¶¡±½ÌªÈí½ºÄÒButylphthalide Soft Capsules
˳Ӧ֢£ºÓÃÓÚÖÎÁÆÇá¡¢Öжȼ±ÐÔȱѪÐÔÄÔ×äÖС£¡£¡£¡£¡£¡£
-

¶¡±½ÌªÂÈ»¯ÄÆ×¢ÉäÒº
¶¡±½ÌªÂÈ»¯ÄÆ×¢ÉäÒºButylphthalide and Sodium Chloride Injection
¶¡±½ÌªÂÈ»¯ÄÆ×¢ÉäÒº
¶¡±½ÌªÂÈ»¯ÄÆ×¢ÉäÒºButylphthalide and Sodium Chloride Injection
˳Ӧ֢£ºÓÃÓÚ¼±ÐÔȱѪÐÔÄÔ×äÖл¼ÕßÉñ¾¹¦Ð§È±ËðµÄ¸ÄÉÆ¡£¡£¡£¡£¡£¡£
-

¶È¶÷Ì©
ÐÂÐ͹Ú×´²¡¶¾±äÒìÖêmRNAÒßÃç(º¬BA.5½¹µãÍ»±äλµã)COVID-19 mRNA Vaccine(containing BA.5 key mutations)
¶È¶÷Ì©
ÐÂÐ͹Ú×´²¡¶¾±äÒìÖêmRNAÒßÃç(º¬BA.5½¹µãÍ»±äλµã)COVID-19 mRNA Vaccine(containing BA.5 key mutations)
˳Ӧ֢£º±¾Æ·ÊÊÓÃÓÚÔ¤·ÀÐÂÐ͹Ú×´²¡¶¾(SARS-COV-2)ѬȾÒýÆðµÄ¼²²¡(COVID-19)¡£¡£¡£¡£¡£¡£
-

Ã÷¸´ÀÖ
×¢ÉäÓÃÖØ×éÈËTNK×éÖ¯ÐÍÏËÈÜøԼ¤»î¼ÁRecombinant Human TNK Tissue-type Plasminogen Activator for Injection
Ã÷¸´ÀÖ
×¢ÉäÓÃÖØ×éÈËTNK×éÖ¯ÐÍÏËÈÜøԼ¤»î¼ÁRecombinant Human TNK Tissue-type Plasminogen Activator for Injection
˳Ӧ֢£º1¡¢ÓÃÓÚ·¢²¡6СʱÒÔÄڵļ±ÐÔÐ£ËÀ»¼ÕßµÄÈÜ˨ÖÎÁÆ¡£¡£¡£¡£¡£¡£
2¡¢ÓÃÓÚ¼±ÐÔȱѪÐÔ×äÖл¼ÕßµÄÈÜ˨ÖÎÁÆ¡£¡£¡£¡£¡£¡£±ØÐèÔ¤ÏȾÓÉÊʵ±µÄÓ°Ïñѧ¼ì²é£¨ÈçÍ·ÂCTɨÃè»òÕ߯äËû¶Ô³öѪÃô¸ÐµÄÓ°ÏñѧÕï¶ÏÒªÁ죩ɨ³ýÂÄÚ³öѪ֮ºó£¬£¬£¬£¬£¬£¬£¬ÔÚ¼±ÐÔȱѪÐÔ×äÖÐÖ¢×´±¬·¢ºóµÄ4.5СʱÄÚ¾¡¿ì¾ÙÐÐÖÎÁÆ¡£¡£¡£¡£¡£¡£ÖÎÁÆÐ§¹û¾ßÓÐʱ¼äÒÀÀµÐÔ£¬£¬£¬£¬£¬£¬£¬Ô½ÔçÖÎÁÆ£¬£¬£¬£¬£¬£¬£¬»ñÒæµÄ¿ÉÄÜÔ½´ó¡£¡£¡£¡£¡£¡£
